Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 7, 2024--

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,United States ,Christine Regan Lindenboom ,Josh Brodsky ,Akshay Desai ,Simon Fox ,Alnylam Pharmaceuticals ,Health Promotion Series ,Zilebesiran Program Lead At Alnylam ,World Health Organization ,Journal Of The American College Cardiology ,Novartis ,Nasdaq ,Securities Exchange ,American College Of Cardiology ,Linkedin ,Exchange Commission ,Facebook ,Instagram ,Alnylam Pharmaceuticals Nasdaq ,Heart Failure Program ,Alnylam Pharmaceuticals Inc ,Annual Scientific ,Hour Mean ,Orthostatic Hypotension ,Repeat Measure ,Function Impact ,Vice President ,Zilebesiran Program Lead ,Renin Angiotensin Aldosterone System ,Enhanced Stabilization Chemistry Plus ,Nobel Prize Winning ,Securities Act ,Securities Exchange Act ,Quarterly Reports ,World Health ,Published September ,American College ,Business Wire ,Region ,